Hi there,
Great news! Today, the FDA approved the first over-the-counter birth control pill in the United States.
This is a major milestone for contraceptive access. Opill, a progestin-only birth control pill, will be the first birth control pill in the United States to be available without a prescription. Its approval, without any age restrictions, removes a huge and medically unnecessary barrier to access.
Add your name to thank the FDA for following the science and making contraception more accessible to every body. [[link removed]]
THANK THE FDA [[link removed]]
The FDA (U.S. Food and Drug Administration) is an agency that makes decisions based on science and data to review and approve various consumer products and medications and determines how they can be safely used by the public. Its decision to approve Opill reflects decades of data that shows birth control pills are safe and effective for over-the-counter use.
The fight to make birth control more accessible has been years in the making, and this moment is a huge victory for reproductive freedom advocates. Young people were essential in making this possible—and so were supporters like you. Join us in thanking the FDA for following the science and approving the first over-the-counter birth control pill. [[link removed]]
NARAL Pro-Choice America
With the support of people like you, we can make sure that freedom is for every body.
GIVE MONTHLY [[link removed]] DONATE NOW [[link removed]]
[link removed]
[link removed]
[link removed]
DONATE [[link removed]]
VOLUNTEER [[link removed]]
BECOME A MEMBER [[link removed]]
Text NARAL to 59791 to join our mobile activist list!
Message and data rates apply. Frequency varies. Text STOP to end. Text HELP for help. Privacy Policy and Terms & Conditions [[link removed]]
We're grateful for your interest in NARAL Pro-Choice America and support for the reproductive freedom movement, but we understand if you want to receive fewer emails [[link removed]] or unsubscribe [[link removed]] .
© Copyright 2023 NARAL Pro-Choice America
1725 Eye St. NW, Suite 900, Washington, DC 20006
All rights reserved. [[link removed]]
